<DOC>
	<DOCNO>NCT03000439</DOCNO>
	<brief_summary>A randomize withdrawal study responder open-label treatment tofacitinib randomize 1:1 ratio tofacitinib placebo double-blind phase . In double-blind phase `` time sJIA flare '' evaluate primary endpoint subject discontinue experience sJIA flare . Once 31 flare report study complete .</brief_summary>
	<brief_title>A Safety , Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>active sJIA disease accord ILAR criterion least 6 week screen Treatment stable dos methotrexate ( MTX ) ≤25 mg/week ≤20 mg/m2/week , whichever low , permit ; Treatment stable dose oral prednisone ≤1 mg/kg/day maximum 30 mg/day , equivalent , least 1 week first study drug dose permit . Previous JIA treatment tofacitinib ; Current symptom finding myocarditis , endocarditis minimal pericardial effusion associate sJIA . Current symptoms finding minimal pleuritis sJIA Subjects previously fail treatment two biologic DMARDs . Note : subject allow previously fail one biologic DMARD , forty ( 40 ) percent subject allow previously fail two biologic DMARDs provide washout period respect .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>systemic Juvenile Idiopathic Arthritis</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>Tofacitinib</keyword>
	<keyword>sJIA</keyword>
	<keyword>CP-690 550</keyword>
</DOC>